How GW Pharma Won CBD

GW Pharma's CBD Success As of this writing, GW Pharma’s CBD drug Epidiolex has been approved for treating profound refractory pediatric epilepsy syndromes (Dravet syndrome and Lennox Gastaut syndrome) as well as seizures associated with tuberous sclerosis complex (TSC) in patients one year of age or older.  The product is a very simple, orally-administered formulation

By |2020-09-22T10:47:27-06:00September 21st, 2020|Regulatory|

Three Keys To Success With Marijuana Regulatory Agencies

Written by: Craig Small, Hoban Law Group September 2020 In the multiverse of marijuana regulatory agency interactions between marijuana business licenses, their counsel, and regulatory agency officials, a few modes of operation have emerged as critical to an attorney’s success in negotiating with such officials on behalf of their clients.  Certainly, there are an infinite

By |2020-09-08T16:12:57-06:00September 8th, 2020|Regulatory|

Cannabis Edibles and Allergens

Written By: Brandon Dorsky Determining what edible to consume is an art all by itself. Making that choice when you suffer from food allergies often makes the decision all the more challenging. Despite the continued federal illegality of cannabis, cannabis products are still obligated to abide by Federal labeling requirements requiring the disclosure and identification

By |2020-07-28T12:19:24-06:00July 27th, 2020|Regulatory|

Beyond Marijuana: How Psychedelics Became the Next Big Wave

Feeling kind of blue?  Experiencing intimacy issues or just plain anxious?  Help may be right around the corner in the form of legalized hallucinogens.  Ranging from plant drugs, like mushroom-derived psilocybin and cactus-derived peyote, to synthetics like Lysergic acid diethylamide (“LSD”) and Methyl​enedioxy​methamphetamine (“MDMA"), hallucinogens are increasingly used to treat recognized disorders, including depression, anxiety,

By |2020-07-02T09:30:42-06:00March 20th, 2020|Regulatory|

California Suspends Additional Cannabis Licenses

Some California licensees are starting off 2020 in a regulatory predicament. In early January, California’s Bureau of Cannabis Control (“BCC”) welcomed the new year with a bang by suspending another 252 cannabis licenses. This most recent round of suspensions comes on the heels of the BCC’s, and other regulating agencies, first round of suspensions. In

By |2020-07-02T09:30:34-06:00February 13th, 2020|Regulatory|

The Four Regulatory Lanes of the Cannabis Plant

“Busted, down on Bourbon Street Set up, like a bowlin' pin Knocked down, it gets to wearin' thin They just won't let you be” Last December, I had the pleasure of being invited to speak at the United Nations Commission on Narcotic Drugs. The conference was a tremendous success, even though it didn’t bring to

By |2019-12-18T11:43:09-07:00November 14th, 2019|Regulatory|

The End is Nigh

A Non-Alarmist Perspective on the Vape Crisis Recently, there’s been an influx of reported fatalities that health officials in California, Indiana, Illinois, Oregon, and Minnesota have linked to vaping. Public officials, including President Trump, have called for additional regulations and an outright ban on electronic vapes. This is certainly a tragedy, and cause for concern,

By |2020-07-02T09:30:46-06:00September 24th, 2019|Regulatory|

Regulation of different CBD product types

As FDA and industry determine the legality of CBD in supplements and foods, brands are releasing oral ingestibles, cosmetics and less traditional products types. Hemp foods are nothing new in the United States. In the early 2000s, sterilized (hulled) hempseeds, cold-pressed hempseed oil and other similar products were widely available. Since then, Congress enacted laws

By |2019-12-18T12:48:39-07:00April 3rd, 2019|Regulatory|

NHL Marijuana Policy Approach As A Role Model For Other Professional Sports

With thirty-three states and the District of Columbia legalizing marijuana in some form or another in the United States, it is safe to say marijuana use is gaining social and cultural acceptance. But as public acceptance of marijuana use continues its mainstream march forward there are still bastions of resistance that maintain a dissimilar

By |2019-12-18T12:49:28-07:00April 3rd, 2019|Regulatory|

Concerns and Limitations for Multistate Producers Looking to Market CBD

Passage of the 2018 Farm Bill has undoubtedly provided comfort to large-scale retailers looking to bring hemp-derived products to retail shelves across the country. The language in the new law clarifies and affirms that hemp is not to be treated as a controlled substance as scheduled under the Controlled Substances Act of 1970 (CSA), which

By |2019-12-18T12:50:26-07:00April 2nd, 2019|Regulatory|
Go to Top